These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 16087771

  • 1. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.
    Tintner R, Manian P, Gauthier P, Jankovic J.
    Arch Neurol; 2005 Aug; 62(8):1290-5. PubMed ID: 16087771
    [Abstract] [Full Text] [Related]

  • 2. Pergolide-induced pleuropulmonary fibrosis.
    Bleumink GS, van der Molen-Eijgenraam M, Strijbos JH, Sanwikarja S, van Puijenbroek EP, Stricker BH.
    Clin Neuropharmacol; 2002 Aug; 25(5):290-3. PubMed ID: 12410064
    [Abstract] [Full Text] [Related]

  • 3. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.
    Andersohn F, Garbe E.
    Mov Disord; 2009 Jan 15; 24(1):129-33. PubMed ID: 19170199
    [Abstract] [Full Text] [Related]

  • 4. Pleuropulmonary disease due to pergolide use for restless legs syndrome.
    Danoff SK, Grasso ME, Terry PB, Flynn JA.
    Chest; 2001 Jul 15; 120(1):313-6. PubMed ID: 11451859
    [Abstract] [Full Text] [Related]

  • 5. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.
    Dewey RB, Reimold SC, O'Suilleabhain PE.
    Arch Neurol; 2007 Mar 15; 64(3):377-80. PubMed ID: 17353380
    [Abstract] [Full Text] [Related]

  • 6. [Pergolide-induced pleural effusion in a patient with juvenile parkinsonism].
    Kuwabara T.
    Rinsho Shinkeigaku; 2002 Aug 15; 42(8):757-60. PubMed ID: 12701223
    [Abstract] [Full Text] [Related]

  • 7. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
    Grosset K, Needleman F, Macphee G, Grosset D.
    Mov Disord; 2004 Nov 15; 19(11):1370-4. PubMed ID: 15389984
    [Abstract] [Full Text] [Related]

  • 8. Rounded atelectasis and respiratory compromise secondary to pergolide use.
    Bloom CI, Wilson GE.
    Respirology; 2009 Aug 15; 14(6):906-7. PubMed ID: 19659834
    [Abstract] [Full Text] [Related]

  • 9. Pleural fibrosis associated with dihydroergocryptine treatment.
    Oechsner M, Groenke L, Mueller D.
    Acta Neurol Scand; 2000 Apr 15; 101(4):283-5. PubMed ID: 10770528
    [Abstract] [Full Text] [Related]

  • 10. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
    Razmy A, Lang AE, Shapiro CM.
    Arch Neurol; 2004 Jan 15; 61(1):97-102. PubMed ID: 14732626
    [Abstract] [Full Text] [Related]

  • 11. [Organ changes induced by ergot derivative dopamine agonist drugs: time to change treatment guidelines in Parkinson's disease?].
    Roth J, Ulmanová O, Růzicka E.
    Cas Lek Cesk; 2005 Jan 15; 144(2):123-6. PubMed ID: 15807300
    [Abstract] [Full Text] [Related]

  • 12. Pergolide-induced lung disease in patients with Parkinson's disease.
    Kastelik JA, Aziz I, Greenstone MA, Thompson R, Morice AH.
    Respir Med; 2002 Jul 15; 96(7):548-50. PubMed ID: 12194642
    [No Abstract] [Full Text] [Related]

  • 13. Diagnosis and management of pergolide-induced fibrosis.
    Agarwal P, Fahn S, Frucht SJ.
    Mov Disord; 2004 Jun 15; 19(6):699-704. PubMed ID: 15197712
    [Abstract] [Full Text] [Related]

  • 14. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P, Findley LJ, Jeffs JA, Pearce RK, Bain PG.
    Mov Disord; 2003 Feb 15; 18(2):176-80. PubMed ID: 12539211
    [Abstract] [Full Text] [Related]

  • 15. Switching from pergolide to pramipexole in patients with Parkinson's disease.
    Hanna PA, Ratkos L, Ondo WG, Jankovic J.
    J Neural Transm (Vienna); 2001 Feb 15; 108(1):63-70. PubMed ID: 11261747
    [Abstract] [Full Text] [Related]

  • 16. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
    Antonini A, Poewe W.
    Lancet Neurol; 2007 Sep 15; 6(9):826-9. PubMed ID: 17706566
    [Abstract] [Full Text] [Related]

  • 17. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease.
    Driver-Dunckley E, Samanta J, Stacy M.
    Neurology; 2003 Aug 12; 61(3):422-3. PubMed ID: 12913220
    [No Abstract] [Full Text] [Related]

  • 18. Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide.
    Jiménez-Jiménez FJ, López-Alvarez J, Sánchez-Chapado M, Montero E, Miquel J, Sierra A, Gutiérrez F.
    Clin Neuropharmacol; 1995 Jun 12; 18(3):277-9. PubMed ID: 8635187
    [Abstract] [Full Text] [Related]

  • 19. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease.
    Ling LH, Ahlskog JE, Munger TM, Limper AH, Oh JK.
    Mayo Clin Proc; 1999 Apr 12; 74(4):371-5. PubMed ID: 10221467
    [Abstract] [Full Text] [Related]

  • 20. Comparing dopamine agonists in Parkinson's disease.
    Bonuccelli U.
    Curr Opin Neurol; 2003 Dec 12; 16 Suppl 1():S13-9. PubMed ID: 15180133
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.